• Product NameVX-222 (VCH-222, Lomibuvir)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityVX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. Phase 2.
• Target NameHCV Protease inhibitor
• CAS No. 1026785-59-0
• Calculated MW 445.61
• Formulation C25H35NO4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1CCC(CC1)C(=O)N(C2CCC(CC2)O)C3=C(SC(=C3)C#CC(C)(C)C)C(=O)O
  Pathways:Microbiology&virology; Proteases/Proteasome
  Receptor:HCV NS5B 1a; HCV NS5B 1b
  Boling pt:
  Melting pt:
  Solubility:DMSO:89 mg/mL (199.72 mM)Ethanol:89 mg/mL (199.72 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Bedard J, et al. J Hepatol, 2009, 50(Suppl 1), S340.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting